Go to the content. | Move to the navigation | Go to the site search | Go to the menu | Contacts | Accessibility

| Create Account

Zanetti, Alessandra (2008) Caratterizzazione molecolare delle variazioni di sequenza del gene hIDS in pazienti affetti da sindrome di Hunter. [Ph.D. thesis]

Full text disponibile come:

Documento PDF

Abstract (english)

Hunter syndrome or mucopolysaccharidosis type II (MPS II) is an X-linked disorder caused by the deficienct activity of the lysosomal enzyme iduronate-2-sulfatase (IDS) causing accumulation of partially degraded dermatan and heparan sulfates in various tissues and progressive impairment of function.
Hunter syndrome is a disease with multiorgan and multisystem involvement that shows a complete spectrum of phenotypes from attenuated to intermediate and severe.
The diagnosis is based on the collection of clinical data, on dosage of urine GAG levels and on mutational analysis of the hIDS gene.
Until recently, the management of Hunter syndrome has been palliative and focused on the treatment of signs and symptoms. Enzyme replacement therapy (ERT) with recombinant human iduronate-2- sulfatase (idursulfase) has lately been introduced. ERT has been shown to improve many of the sign and symptoms and overall wellbeing of patients with MPS II.
The IDS locus, located on Xq27.3-q28, spans a region of 24 kb and contains 9 exons. At 20 kb telomeric and in opposite orientation to the IDS gene, a pseudogene, IDS2, containing sequences homologous to exons 2, 3 and introns 2, 3, 7 is present. To date, more than 330 different mutations have been identified in the IDS gene: 89% being small variations, while 11% major structural alterations. The most common rearrangement is an intrachromosomal homologous recombination event between IDS and IDS-2 sequences.
Fifteen unrelated patients were analyzed in this study, 11 Italian and 4 Brazilian. Among the 15 cases analyzed 16 sequence variations were detected: 12 point mutations or small deletions, one medium size deletion, 2 large deletions, a recombination associated to a deletion. Among them 9 were novel sequence variations and 2 were de novo mutations as the mother didn’t result carrier.
The rarity of the disease and the fact that most mutations are private make evalutation of the genotype-phenotype correlation very difficult.
Among the 15 patients described, 9 showed a severe form of the pathology, 4 an intermediate one and 2 were mild. A genotype-fenotype relationship was attempted for each case. The complete absence of functional enzyme caused by total or partial gene deletion or by gene-pseudogene rearrangement seemed to result in a severe form in the cases analyzed. Genotype-phenotype correlation for point mutations was more complex and a specific discussion was necessary for each sequence variation.
Molecular analysis is a valid method to support clinical and biochemical diagnosis confirming the results obtained from the previous approaches. Gene analysis is the only secure method to identify female carriers among a patient’s relatives and therefore it is essential in genetic counselling. Furthermore, it is useful in prenatal diagnosis in order to detect the mutation carried by a heterozygote mother.

Statistiche Download - Aggiungi a RefWorks
EPrint type:Ph.D. thesis
Tutor:Scarpa, Maurizio
Supervisor:Tomanin, Rosella
Data di deposito della tesi:30 June 2008
Anno di Pubblicazione:30 June 2008
Key Words:gene hIDS, pseudogene IDS-2, mutazioni, ricombinazione, sindrome di Hunter, mucopolisaccaridosi tipo II
Settori scientifico-disciplinari MIUR:Area 06 - Scienze mediche > MED/03 Genetica medica
Struttura di riferimento:Dipartimenti > pre 2012 - Dipartimento di Pediatria
Codice ID:1071
Depositato il:02 Dec 2008
Simple Metadata
Full Metadata
EndNote Format


I riferimenti della bibliografia possono essere cercati con Cerca la citazione di AIRE, copiando il titolo dell'articolo (o del libro) e la rivista (se presente) nei campi appositi di "Cerca la Citazione di AIRE".
Le url contenute in alcuni riferimenti sono raggiungibili cliccando sul link alla fine della citazione (Vai!) e tramite Google (Ricerca con Google). Il risultato dipende dalla formattazione della citazione.

1. Beck M and Wraith E. Update on mucopolysaccharidosis type II. Acta Paediatrica 2007; 96:55 Cerca con Google

2. Birot AM, Bouton O, Froissart R, Maire I, Bozon D. IDS gene-pseudogene exchange responsible for an intragenic deletion in a Hunter patient. Hum Mutat 1996a; 8(1):44-50. Cerca con Google

3. Birot AM, Delobel B, Gronnier P, Bonnet V, Maire I, Bozon D. A 5-megabase familial deletion removes the IDS and FMR-1 genes in a male Hunter patient. Hum Mutat 1996b; 7(3):266-8 Cerca con Google

4. Bondeson ML, Dahl N, Malmgren H, Kleijer WJ, Tönnesen T, Carlberg BM, Pettersson U. Inversion of the IDS gene resulting from recombination with IDS-related sequences is a common cause of the Hunter syndrome. Hum Mol Genet 1995; 4(4):615-21 Cerca con Google

5. Bonnuccelli G, Regis S, Filocamo M, Corsolini F, Caroli, Gatti R. A deletion involving exons 2-4 in the iduronate-2-sulfatase gene of a patient with intermediate Hunter sindrome. Clin Genet 1998; 53:474-477 Cerca con Google

6. Broadhead DM, Kirk JM, Burt AJ, Gupta V, Ellis PM, Besley GT. Full expression of Hunter's disease in a female with an X-chromosome deletion leading to non-random inactivation. Clin Genet 1986; 30(5):392-8. Cerca con Google

7. Brooks DA, Muller VJ, Hopwood JJ. Stop-codon read-through for patients affected by a lysosomal storage disorder. Trends Mol Med 2006; 12(8):367-73. Cerca con Google

8. Bunge S, Rathmann M, Steglic C, Bondeson ML, Tylki-Szymanska A, Popowska E, Gal A. Homologous nonallelic recombination between the iduronate- sulfatase gene and pseudogene cause various intragenic deletion and inversions in patients with mucopolysaccharidosis type II. European Journ Hum Genet 1998; 6(5):492-500 Cerca con Google

9. Bunge S, Steglich C, Beck M, Rosenkranz W, Schwinger E, Hopwood JJ, Gal A. Mutation analysis of the iduronate-2-sulfatase gene in patients with mucopolysaccharidosis type II (Hunter syndrome). Hum Mol Genet 1992; 1(5):335-9. Cerca con Google

10. Clarke JT., Greer WL, Strasberg PM, Pearce RD, Skomorowski MA, Ray PN. Hunter disease (mucopolysaccharidosis type II) associated with unbalanced inactivation of the X chromosomes in a karyotypically normal girl. Am Journ Hum Genet 1991; 49(2):289-297 Cerca con Google

11. Clarke JT, Willard HF, Teshima I, Chang PL, Skomorowski MA. Hunter disease (mucopolysaccharidosis type II) in a karyotypically normal girl. Clin Genet 1990; 37(5):355-362 Cerca con Google

12. Clarke JT, Wilson PJ, Morris CP, Hopwood JJ, Richards RI, Sutherland GR, Ray PN. Characterization of a deletion at Xq27-q28 associated with unbalanced inactivation of the nonmutant X chromosome. Am Journ Hum Genet 1992; 51(2):316-322 Cerca con Google

13. Cudry S, Tigaud I, Froissart R, Bonnet V, Maire I, Bozon D. MPSII in females: molecular basis of two different cases. J Med Genet 2000; 37(10):E29 Cerca con Google

14. Daniele A, Tomanin R, Villani GR, Zacchello F, Scarpa M, Di Natale P. Uptake of recombinant iduronate-2-sulfatase into neuronal and glial cells in vitro. Biochim Biophys Acta 2002; 1588(3):203-9 Cerca con Google

15. den Dunnen JT, Antonarakis SE. Nomenclature for the description of human sequence variations. Hum Genet. 2001 Jul;109(1):121-4. Cerca con Google

16. Desnick RJ. Enzyme replacement and enhancement therapies for lysosomal diseases. J Inherit Metab Dis 2004; 27(3):385-410 Cerca con Google

17. Filocamo M, Bonuccelli G, Corsolini F, Mazzotti R, Cusano R, Gatti R. Molecular analysis of 40 Italian patients with mucopolysaccharidosis type II: New mutations in the iduronate-2-sulfatase (IDS) gene. Hum Mutat 2001; 18(2):164-5 Cerca con Google

18. Flomen RH, Green PM, Bentley DR, Giannelli F, Green EP. Detection of point mutations and a gross deletion in six Hunter syndrome patients. Genomics 1992; 13(3):543-50. Cerca con Google

19. Froissart R, Blond JL, Maire I, Guibaud P, Hopwood JJ, Mathieu M, Bozon D Hunter syndrome: gene deletions and rearrangements. Hum Mut 1993; 2(2):138-40. Cerca con Google

20. Froissart R, Maire I, Bonnet V, Levade T, Bozon D. Germline and somatic mosaicism in a female carrier of Hunter disease. J Med Genet 1997; 34(2):137-40 Cerca con Google

21. Froissart R, Moreira da Silva I, Maire I. Mucopolysaccharidosis type II: an update on mutation spectrum. Acta paediatrica 2007; 96:71-77 Cerca con Google

22. Goldenfum SL, Young E, Michelakakis H, Tsagarakis S, Winchester B Mutation analysis in 20 patients with Hunter disease. Hum Mut 1996; 7(1):76-8. Cerca con Google

23. Gort L, Chabás A, Coll MJ Hunter disease in the Spanish population: Molecular analysis in 31 families. J Inherit Metab Dis 1998a; 21(6):655-61; a Cerca con Google

24. Gort L, Coll MJ, Chabas A. Mutations in the iduronate-2-sulfatase gene in 12 Spanish patients with Hunter disease. Hum Mutat 1998b; Suppl 1:S66-8; b Cerca con Google

25. Gort L, Chabás A, Coll MJ. A new polymorphism in the iduronate-2-sulphatase gene. Implications for the diagnosis of Hunter disease. J Inherit Metab Dis 1999; 22(7):844 Cerca con Google

26. Hartog C, Fryer A, Upadhyaya M. Mutation analysis of iduronate-2-sulphatase gene in 24 patients with Hunter syndrome: Characterisation of 6 novel mutations Hum Mutat 1999; 14(1):87. Cerca con Google

27. Hopwood JJ, Bunge S, Morris CP, Wilson PJ, Steglich C, Beck M, Schwinger E, Gal A. Molecular basis of mucopolysaccharidosis type II: mutations in the iduronate-2-sulphatase gene. Hum Mut 1993; 2:435-442 Cerca con Google

28. Karsten SL, Voskoboeva E, Tishkanina S, Pettersson U, Krasnopolskaja X, Bondeson ML. Mutational spectrum of the iduronate-2-sulfatase (IDS) gene in 36 unrelated Russian MPS II patients. Hum Genet 1998; 103(6):732-5. Cerca con Google

29. Kato T, Kato Z, Kuratsubo I, Tanaka N, Ishigami T, Kajihara J, Sukegawa-Hayasaka K, Orii K, Isogai K, Fukao T, Shimozawa N, Orii T, Kondo N, Suzuki Y. Mutational and structural analysis of Japanese patients with mucopolysaccharidosis type II. J Hum Genet 2005; 50(8):395-402. Epub 2005 Aug 30 Cerca con Google

30. Lagerstedt K, Carlberg BM, Karimi-Nejad R, Kleijer WJ, Bondeson ML Analysis of a 43.6 kb deletion in a patient with Hunter syndrome (MPSII): identification of a fusion trascript including sequence from the gene W and IDS gene. Hum Mutat 2000; 15:324-331 Cerca con Google

31. Lagerstedt K, Karsten SL, Carlberg BM, Kleijer WJ, Tönnesen T, Pettersson U, Bondeson ML. Double-strand breaks may initiate the inversion mutation causing the Hunter syndrome. Hum Mol Genet 1997; 6(4):627-33 Cerca con Google

32. Li P, Bellows A B, Thompson J N Molecular basis of iduronate-2-sulfatase gene mutations in patients with mucopolysaccharidosis type II (Hunter syndrome). J Med Genet 1999; 36:21-27 Cerca con Google

33. Li P, Huffman P, Thompson JN. Mutations of the iduronate-2-sulfatase gene on a T146T background in three patients with Hunter syndrome. Hum Mutat 1995; 5(3):272-4. Cerca con Google

34. Lissens W, Seneca S, Liebaers I. Molecular analysis in 23 Hunter disease families. J Inherit Metab Dis. 1997 Jul;20(3):453-6 Cerca con Google

35. Lualdi S, Di Rocco M, Corsolini F, Spada M, Bembi B, Cotugno G, Battini R, Stroppiano M, Pittis MG, Filocamo M. Identification of nine new IDS alleles in mucopolysaccharidosis II. Quantitative evaluation by real-time RT-PCR of mRNAs sensitive to nonsense-mediated and nonstop decay mechanisms. Biochim Biophys Acta 2006; 1762(4):478-84. Cerca con Google

36. Lualdi S, Regis S, Di Rocco M, Corsolini F, Stroppirano M, Antuzzi D, Filocamo M. Characterization of IDS gene-pseudogene recombinantions in eight patients with MPS type II revealed by a rapid PCR-based method. Hum Mut 2005; 25:491-497 Cerca con Google

37. Martin R, Beck M, Eng C, Giugliani R, Harmatz P, Munõz V, Muenzer J. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Paediatrics 2008; 121(2):377-86. Cerca con Google

38. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999; 281:249-254 Cerca con Google

39. Moreira Da Silva I, Froissart R, Marques Dos Santos H, Caseiro C, Maire I, Bozon D Molecular basis of Mucopolysaccharidosis type II in Portugal: identification of four novel mutations. Clin Genet 2001; 60(4):316-8 Cerca con Google

40. Mossman J, Blunt S, Stephens R, Jones E. E., Pembrey M. Hunter's disease in a girl: association with X:5 chromosomal translocation disrupting the Hunter gene. Arch Dis Child 1983; 58(11): 911-915 Cerca con Google

41. Neufeld EF and Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B (eds) The Metabolic and Molecular Basis of Inherited Disease, 8 ed, Vol III. McGraw-Hill, Medical Publishing Division, p 3421. 2001. Cerca con Google

42. Parkinson-Lawrence E, Turner C, Hopwood JJ, Brooks D. Analysis of normal and mutant iduronate-2-sulphatase conformation. Biochem J 2005; 386(Pt 2):395-400 Cerca con Google

43. Rathmann M, Bunge S, Beck M, Kresse H, Tylki-Szymanska A, Gal A. Mucopolysaccharidosis type II (Hunter syndrome): mutation "hot spots" in the iduronate-2-sulfatase gene. Am J Hum Genet. 1996 Dec;59(6):1202-9 Cerca con Google

44. Ricci V, Filocamo M, Regis S, Corsolini F, Stroppiano M, Di Duca M, Gatti R. Expression studies of two novel in CIS-mutations identified in an intermediate case of Hunter syndrome. Am J Med Genet A 2003; 120A(1):84-7 Cerca con Google

45. Roberts SH, Upadhyaya M, Sarfarazi M, Harper PS. Further evidence localising the gene for Hunter's syndrome to the distal region of the X chromosome long arm. Journ Med Genet 1989; 26(5):309-313 Cerca con Google

46. Sardiello M, Annunziata I, Roma G, Ballabio A. Sulfatases and sulfatase modifying factors: an exclusive and promiscuous relationship. Hum Mol Genet 2005; 14(21):3203-17 Cerca con Google

47. Schwartz IV, Ribeiro MG, Mota JG, Toralles MB, Correia P, Horovitz D, Santos ES, Monlleo IL, Fett-Conte AC, Sobrinho RP, Norato DY, Paula AC, Kim CA, Duarte AR, Boy R, Valadares E, De Michelena M, Mabe P, Martinhago CD, Pina-Neto JM, Kok F, Leistner-Segal S, Burin MG, Giugliani R. A clinical study of 77 patients with mucopolysaccharidosis type II. Acta Paediatr Suppl 2007; 96(455):63-70. Cerca con Google

48. Sukegawa K, Kato Z, Nakamura H, Tomatsu S, Fukao T, Kuwata K, Orii T, Kondo N. Effect of Hunter disease (mucopolysaccharidosis type II) mutations on molecular phenotypes of iduronate-2-sulfatase: enzymatic activity, protein processing and structural analysis. J Inherit Metab Dis 2006; 29:755-761 Cerca con Google

49. Sukegawa K, Tomatsu S, Fukao T, Iwata H, Song XQ, Yamada Y, Fukuda S, Isogai K, Orii T. Mucopolysaccharidosis type II (Hunter disease): identification and characterization of eight point mutations in the iduronate-2-sulfatase gene in Japanese patients. Hum Mutat 1995; 6(2):136-43 Cerca con Google

50. Sukegawa K, Tomatsu S, Tamai K, Ikeda M, Sasaki T, Masue M, Fukuda S, Yamada Y, Orii T. Intermediate form of mucopolysaccharidosis type II (Hunter disease): a C1327 to T substitution in the iduronate sulfatase gene. Biochem Biophys Res Commun 1992; 183(2):809-13 Cerca con Google

51. Sukegawa K, Matsuzaki T, Fukuda S, Masuno M, Fukao T, Kokuryu M, Iwata S, Tomatsu S, Orii T, Kondo N. Brother/sister siblings affected with Hunter disease: evidence for skewed X chromosome inactivaction. Clin Genet 1998; 53(2):96-101 Cerca con Google

52. Sukegawa K, Song XQ, Masuno M, Fukao T, Shimozaua N, Fukuda S, Isogai K, Nishio H, Matsuo M, Tomatsu S, Kondo N, Orii T. Hunter disease in a girl caused by R468Q mutation in the iduronate-2-sulfatase gene and skewed inactivation of the X chromosome carrying the normal allele. Hum Mutat 1997; 10(5):361-367 Cerca con Google

53. Timms KM, Bondenson ML, Ansari-Lari MA, Lagerstedt K, Muzny DN, Dugan-Rocha SP, Nelson DL, Pettersson U, Gibbs RA. Molecular and phenotypic variation in patients with severe Hunter syndrome. Hum Mol Genet 1997; 6(3):479-86 Cerca con Google

54. Timms KM, Huckett LE, Belmont JW, Shapira SK, Gibbs RA. DNA deletion confined to the iduronate-2-sulfatase promoter abolishes IDS gene expression. Hum Mutat 1998; 11(2):121-6 Cerca con Google

55. Vafiadaki E, Cooper A, Heptinstall LE, Hatton CE, Thornley M, Wraith JE. Mutation analysis in 57 unrelated patients with MPS II (Hunter's disease). Arch Dis Child 1998; 79(3):237-41 Cerca con Google

56. Vellodi A, Young E, Cooper A, Lidchi V, Winchester B, Wraith JE. Long-term follow-up following bone marrow transplantation for Hunter disease. J Inherit Metab Dis 1999; 22(5):638-48 Cerca con Google

57. Vellodi A. Lysosomal storage disorder. British Journal of Haematology 2004; 128:413-431 Cerca con Google

58. Villani GR, Balzano N, Grosso M, Salvatore F, Izzo P, Di Natale P Mucopolysaccharidosis type II: identification of six novel mutations in Italian patients. Hum Mut 1997; 10(1):71-5. Cerca con Google

59. Villani GR, Daniele A, Balzano N, Di Natale P. Expression of five iduronate-2-sulfatase site-directed mutations. Biochim Biophys Acta. 2000 Jun 15;1501(2-3):71-80 Cerca con Google

60. Whitley CB, Anderson RA, Aronovich EL, Crotty PL, Anyane-Yeboa K, Russo D, Warburton D. Caveat to genotype-phenotype correlation in mucopolysaccharidosis type II: discordant clinical severity of R468W and R468Q mutations of the iduronate-2-sulfatase gene. Hum Mutat 1993; 2(3):235-7 Cerca con Google

61. Winchester B, Vellodi A, Young E. The molecular basis of lysosomal storage diseases and their treatment. Biochem Soc Trans 2000; 28(2):150-154 Cerca con Google

62. Winchester B, Young E, Geddes S, Genet S, Hurst J, Middleton-Price H, Williams N, Webb M, Habel A, Malcom S. Female twin with Hunter disease due to nonrandom inactivation of the X-chromosome: a consequence of twinning. Am Journ Med Genet 1992; 44(6):834-838 Cerca con Google

63. Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N, Meldgaard Lund A, Malm G, Van der Ploeg AT, Zeman J. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 2008; 167(3):267-77 Cerca con Google

Download statistics

Solo per lo Staff dell Archivio: Modifica questo record